2012 NanoFar School

1st NanoFar School

University of Angers – 22-26 October 2012

The NanoFar Consortium has organized its first Autumn School, which has been held at the University of Angers from Monday 22nd to Friday 26th of October, 2012.






The 1st NanoFar school has brought together professors from universities composing the NanoFar consortium, NanoFar PhD students, and PhD students who wanted to improve their skills in nanomedicine.

This School aimed to favour exchanges between all the actors and has allowed all PhD students to discuss their projects.


The school has proposed four classes a day (click here to see the program and the speakers).

The classes has covered all the needed aspects related to nanomedicine:

Design of nanomedicine devices, nanomedicines for diagnosis and imaging, responsive polymers and nanocarriers, nanomedicine interactions with biological systems, targeted nanotherapeutics, nanomedicine and radiopharmaceutics.


The courses offered during this week has covered the principal subjects of nanomedicine and pharmaceutical innovation.

Furthermore, this week has been dotted with some events as: a conference with the industrial partners, a poster exhibition proposed by the University of Angers and Nantes’ PhD students …

Click here to download the program as PDF format

Click here to see interviews of participants


NanoFar Schools

Each year, a School with lectures, workshops and round tables is scheduled in a partner university.

The schools include:

  • 2 daylong Introductory Cross-Disciplinary Research Training sessions, dedicated to the teaching of fundamental principles of drug delivery to biologists and nanomedicine to physical scientists to maximise cross-disciplinary outputs of the EMJD. Local lecturers give these courses which are restricted to all new PhD students,
  • 5 days consisting of lectures (covering all relevant aspects related to nanomedicine as design of nanodevices, nanomedicines for diagnosis and imaging, responsive polymers and nanocarriers…), round tables, industrial and clinical workshops, poster sessions and social events.

These schools help promote exchanges between all participants (students, professors, industrial partners) and allow all PhD students to discuss their thesis projects.

The schools are also open to all PhD students from European and non-European universities wishing to improve their knowledge on nanomedicine through courses provided by top scientists.

More details on….

2018 NanoFar School 2017 NanoFar School 2015 NanoFar School
2014 NanoFar School 2013 NanoFar School 2012 NanoFar School

Associated partners


Affilogic In-Cell-Art
Carlina Technologies Kitozyme
IPSEN Regentec


Atlanpôle Biotherapies Biowin 


University Hospital of Angers  University Hospital of Nantes
Hospital of Liège   Hospital of Santiago de Compostela XXI de Santiago de Compostela (Hospitais, Centros de Saúde, Casas do Mar e Consultorios de Santiago e Barbanza)


Unicamp (Brazil)   University of La Plata (Argentina)  
CSIR (South Africa)   Unimore (Italy)  
School of Medicine and AMBER
Trinity College Dublin (Ireland)

The University of Santiago de Compostela

The “Campus Vida” project of the USC has been recognized as one of the 9 International Campus of Excellence in Spain, and nanomedicine is one of its main strategic axes. In this framework, the USC supports decidedly the NanoFar initiative. It will dedicate strong research teams belonging to the School of Pharmacy, Medicine and Chemistry, which have internationally recognized expertise in the most relevant fields covered by nanomedicine, to implement it.

The Drug Delivery Research Group (NANOBIOFAR) is the pioneer group of research in nanomedicine in Spain. This group has developed a number of collaborations with several institutions around the world, as well as with a significant number of pharmaceutical companies and it is also actively involved in the European Technology Platform of Nanomedicine.

NANOBIOFAR will manage PhD programme through concerted supervising and training actions in collaboration with the groups of Investigation in Oncology, Nanotechnology and also with the biotech company Advancell S.A. Their skills linked to targeting therapies, polymeric nanostructures and biomedical applications will perfectly complete the NanoFar Program.
USC will provide platforms including a variety of techniques, from physical chemical characterization towards in vivo evaluation. The key staff of the USC is committed to organize a summer/winter school for each PhD promotion and will closely collaborate with the other partners in the organization of their respective courses. It will also be responsible for the yearly selection and evaluation of candidates for the doctoral school. The USC will elaborate, standardize and distribute all required documents (including e-tools), and will coordinate the whole activity of candidate selection-evaluation within the consortium.

Website: Universidade de Santiago de Compostela


The University of Nottingham

The School of Pharmacy at the University of Nottingham carries out research and training on the synthesis, characterization and biomedical applications of new drugs and drug delivery materials, as well as the detailed study of existing biomaterials and drug delivery systems at the molecular, cellular and macro scale.
All of these aspects particularly well complement the other teams of the consortium. The teams have an international reputation for ‘smart’ materials and polymer-biopolymer conjugates and a world-leading role in tissue engineering and regenerative medicine. They have pioneered scanning probe microscopies and spectroscopies, and high-throughput surface analytical techniques for pharmaceutical applications. Two groups are working on the development of nanosensors for use in live cell imaging on chemical synthesis and drug-carrier formulations.

Within the Nanofar consortium, the Nottingham group will be in charge of the professional insertion of the PhD researchers. The School of Pharmacy at Nottingham has a proven track record in provision of innovative training to equip scientists for careers in the pharmaceutical area and for the future in nanomedicine. The quality of doctoral programmes has been recognised by the EPSRC and AstraZeneca awards to establish a Doctoral Training Centre in Targeted Therapeutics and a Marie-Curie Training Site in Drug Delivery and Tissue Engineering. In addition the School is  partner in the Regenerative Medicine Doctoral Training Centre, also funded by the EPSRC. Those training programmes that are innovative, industrially relevant and end-use oriented will be applied across the NanoFar consortium to immerse PhD researchers in a wide range of scientific, professional and personal development activities in order to ensure a successful transition between the university and a pharmaceutical career.

Website: University of Nottingham


Université catholique de Louvain

The  Louvain Drug Research Institute (LDRI) at UCL has a multidisciplinary research expertise in the field of nanomedecine, including formulation and use for diagnosis, therapeutics and regenerative medicine. Internationally-recognized laboratories of drug delivery / pharmaceutics, cancer, magnetic resonance imaging are involved in the proposal and collaborate on nanomedicine with chemistry and clinical labs.
LDRI at UCL has long-standing experience in the training of PhD students which are supervised by doctoral committees. The PhD students studying at UCL are in contact with an international scientific community, and can develop new competences (scientific communication, project management, working within networks … ). It is well-organised to welcome foreign PhD students: among the 50 PhD students registered, one third are foreign visitors.

LDRI at UCL, as a partner of the EMJD NanoFar, will actively participate in the supervisory and management boards so as to ensure good coordination between all the NanoFar partners.
UCL will dedicate 2 PhD to this supervision, a member of administrative staff to the project management and a financial staff for the reallocation of the Erasmus Mundus fellowships to PhD candidates.

LDRI at UCL has selected putative PhD Supervisors with excellent track records. These supervisors will act in the twinning PhD project. UCL will support the PhD candidates enrolled in its institution in their visa process and their integration in the campus and offer services such as language training.
LDRI at UCL is committed to organise a doctoral school once in the PhD curriculum and to give support to other schools organised in the other partner institutions. It will offer students the option to enroll in existing and established optional PhD courses throughout the academic year.

Website: Université catholique de Louvain


The University of Liège

The ULg is one of the three main universities of the French Community of Belgium, hosting 20 000 students, which 23% are foreign. ULg was ranked 201 worldwide in the 2007 Time Higher Education and 9th in the 2008 top-10 international ranking of The Scientist for post-docs and was awarded by the “HR Strategy for researchers” European label. ULg will focus its research on the synthesis and characterization of materials particularly dedicated to health applications.Professors bring complementary expertise in the characterization of these materials in interactions with biological systems.

The ULg forms many PhDs in a wide range of disciplines, including sciences. The Facuty of Sciences has 247 Phds registered, of which 26 % are from abroad and 20 joint PhDs. Joint teams participating to this program provide a high level education offer for PhDs in products and materials synthesis and characterization for nanomedicine application. They are part of doctoral schools and most of them of an international institute (European Multimaterial Institute from NoE-FAME / FP6), allowing a joint education of PhDs. They have a strong expertise to organise a joint doctoral school in the field of nanomedicine by delivering lectures, giving access to renown research structures on remarkable tools, equipments and technologies, providing a wealthy environment to develop advanced research in the synthesis, engineering and study of materials and products at the basis of the science needed for advanced nanomedicine developments and thus forms valuable PhDs in this emerging field.

Website:  University of Liege


The University of Nantes


The doctoral school Biology and Health coordinates the training of 300 PhD within the UN, the National Veterinary School of Nantes and the University of Angers.
During a three to four year training programme, students participate in academic activities and develop  independent research projects, within the 17 affiliated research laboratories, which, at UN, belong to the Research Institute of Therapeutic (IFR26). The major research topics of this Institute, which employs more than 800 persons, are focused on cancer therapy, cardiovascular diseases, immunology and transplantation, digestive diseases and nutrition, osteo-articular diseases, biotherapies and biotechnology. IFR26 also provides a modern learning environment with his core facilities in transcriptomic, and proteomic, production of pre-clinical viral vector, a functional exploration platform with transgenic rats, cellular imaging and a clinical investigation center.

UN will actively participate in the supervisory and management boards so that to ensure a good coordination between all the NanoFar partners. The Doctoral School will dedicate an administrative staff to the project management. UN has selected putative PhD Supervisors with excellent track records. These supervisors will act in the twinning PhD project. UN will support the PhD candidates enrolled in its institution in their visa process and their integration in the campus and offer services such as language training. UN, through its doctoral school, will provide core skills and introductory cross-disciplinary training sessions in nanomedicine at the start of the training period in addition to existing and established optional PhD courses throughout the academic year. UN will organise specific workshops for all the students enrolled this EMJD program in its field of expertise such as: radiopharmaceutic and targeted radionucleide therapy, molecular imaging, molecular targeting.

Website: University of Nantes


The University of Angers

The University of Angers (UA) is a comprehensive public university with 1000 permanent faculties, 18 500 students. 20% of its doctoral students are in Biology and Health.
Local PhD training is achieved through strong research teams, totalling 240 staff belonging to the Research Institute in Cell Interactions and Therapeutic Applications and the Regional doctoral school in Biology and Health of Nantes and Angers. Nanomedicine is a flagship programme of the UA with an internationally recognised research team.The UA has hosted several conferences in nanomedicine, and possesses the necessary facilities, such as the University-Hospital Common Animal Experimentation Centre, to develop nanomedicine devices. It’s a founding member of the Regional Pole of Research and Higher Education (PRES) of the Pays de la Loire for whom research in health is a major priority.

The UA will be the coordinating institution of the NanoFar programme.
The 20 years experience of the International Office in managing European and international programmes, including Tempus and Leonardo, and the international activity of the School of  Pharmacy (numerous Erasmus and other exchanges, member of a Health and Biomedical research consortium) ensure its achievement and specific staff will be hired to in this way.

The International Office has a specific service for incoming students and the Central Research Division provides support for international programmes through the European Unit and the doctoral training centre. All of the EMJD partner institutions are already partners with Angers Health Science researchers. The UA will host kick-off meetings and doctoral training schools, as well as organisational meetings for administrators of the programme. It will take in charge the internal and external communication of the consortium.

Website: University of Angers


The consortium academic partners are at the forefront of developments in nanomedicine at the European level.

They are dedicated to offering the highest quality education through well recognized doctoral school and international programmes. The consortium brings experience in terms of management and organization.

  • The University of Nantes (UN) and the University of Angers (UA) and their Doctoral school in Biology and Health (Director Pr. C.Tellier, UN, Co-Director Pr. F. Boury, UA), innovates across all disciplines linked to nanomedicine design (Pr. J.P. Benoit) use of radiopharmaceuticals (Dr. J. Barbet, Director of Aronax) and their application in therapy (Pr. O. Couturier and Pr. P. Menei) and tissue engineering (Pr. P. Weiss) (in tight collaboration with hospitals where clinical trials on nanomedical devices have been conducted).

Click here to read the University of Angers presentation

Click here to read the University of Nantes presentation

  •  The Université catholique de Louvain (UCL) and the University of Liège (ULg) excel in Doctoral training through Thematic Doctoral School in pharmaceutical sciences (Director Pr. V. Préat) and material chemistry of National Fund of Scientific research. Belgium groups experience in research is complementary through drug delivery systems (Pr. V. Préat), polymer chemistry (Pr. C. Jérome), Cancer research (Pr. O.Feron) and medical imaging (Pr. A. Luxen, Pr. B.Gallez) or nuclear medicine (Pr. R. Huxtin).

Click here to see the Université catholique de Louvain presentation

Click here to see the University of Liège presentation

  •  The University of Nottingham (UNott) has a Doctoral Training Centre in Targeted Therapeutics with strong expertise in polymer conjugates based therapies (Pr. A. Cameron) and a world-leading role in tissue engineering and regenerative medicine (Pr. K.M. Shakesheff).

Click here to see the University of Nottingham presentation

  •  The University of Santiago de Compostela (USC) (International Excellency Campus Vida) has a leading pole in nanotechnologies applied to the design of Drug Delivery Systems (Pr.. M.J Alonso) with strong existing technology transfers towards the clinic (Pr.. R. Lopez) and industry.

Click here to see the University of Santiago de Compostela presentation

The NanoFar consortium forms the largest research community in nanomedicine in Europe. The research laboratories bring together more than 300 researchers in the concerned field.

NanoFar offers a training environment that will inspire students to tackle difficulties associated with the multiple levels of nanomedicine using new and multidisciplinary techniques with a clear translational perspective on bedside-to-bench and bench-to-bedside activities.
This is possible thanks to its associated partners.

Click here to acceed the presentation of NanoFar associated partners